Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives $21.07 Consensus Price Target from Brokerages
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) has been given an average rating of “Moderate Buy” by the seven ratings firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price […]
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) has been given an average rating of “Moderate Buy” by the seven ratings firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price […]
